Details for Patent: 11,826,376
✉ Email this page to a colleague
Which drugs does patent 11,826,376 protect, and when does it expire?
Patent 11,826,376 protects FARXIGA and is included in one NDA.
Protection for FARXIGA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty patent family members in eighteen countries.
Drugs Protected by US Patent 11,826,376
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-002 | Jan 8, 2014 | RX | Yes | Yes | 11,826,376*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,826,376
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019304032 | ⤷ Subscribe | |||
| Australia | 2022201294 | ⤷ Subscribe | |||
| Australia | 2024201641 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
